Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries. Eveliqure is a game-changer amongst vaccine companies, championing novel technologies to make the world safe from diarrhoea. Eveliqure is passionate about improving the quality of life for both the poor and the privileged by providing innovative medical solutions that fight diarrhoeal diseases.
Externer Link zu Eveliqure Biotechnologies
Karl-Farkas-Gasse 22
Vienna, Vienna 1030, AT
Highly relevant read from Gavi, the Vaccine Alliance #vaccineworks
Vaccines are one of our best weapons against antimicrobial resistance by preventing infections - and the need for antibiotics - in the first place. Here are six things you need to know about how vaccines can help prevent #AMR:
As the year draws to a close and we have just marked another step forward in our commitment against #Shigellosis and #ETEC disease with the start of our #Phase1b trial, we wish you all a joyful holiday season filled with warmth, hope, and good health - here's to a new year filled with exciting advancements! 🌟 #BiotechInnovation #HappyHolidays #vaccines #InnovationJourney
🌐 We are thrillled to announce the initiation of our Phase 1b #clinicaltrial for our #ShigETEC vaccine candidate in Bangladesh! This marks a significant milestone in our mission to combat #Shigellosis and #ETEC diseases and contribute to global health. The Phase 1b trial will focus on assessing the safety, tolerability and immunogenicity of ShigETEC at the icddr,b (International Centre for Diarrheal Disease Research, Bangladesh) Clinical Trials Unit in Mirpur, Dhaka Metropolitan area, Bangladesh. We are optimistic about the potential impact of our vaccine on public health in this region and beyond - please find there our press release: https://lnkd.in/dujfMPKf #BiotechInnovation #VaccineDevelopment #GlobalHealth #ClinicalTrials #HealthcareAdvancements
As we enter this year's World #AMR Awareness Week, we are reminded of the critical importance of advancing #research and innovation to address the global threat posed by #drugresistant infections. As the incidence of #antimicrobial and multidrug resistance #Shigella and E.coli continues to rise, we are proud of continuing the development of our #vaccine candidate #shigetec 💊🌐✨ https://lnkd.in/eKwf4NtY #waaw2023 #antimicrobialresistance #vaccinedevelopment #vaccineswork